---
title: "Abelacimab Versus Rivaroxaban in Older Adults With Atrial Fibrillation"
id: "jama-cardiology-6-abelacimab-vs-rivaroxaban-in-older-individuals-with-af"
canonical_url: "https://medichelpline.com/clinical-feed/jama-cardiology-6-abelacimab-vs-rivaroxaban-in-older-individuals-with-af"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "JAMA Cardiology"
source_url: "https://jamanetwork.com/journals/jamacardiology/fullarticle/2844582"
published_at: "2026-03-01T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Abelacimab Versus Rivaroxaban in Older Adults With Atrial Fibrillation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/jama-cardiology-6-abelacimab-vs-rivaroxaban-in-older-individuals-with-af
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** JAMA Cardiology
- **Source URL:** [Original Journal Publication](https://jamanetwork.com/journals/jamacardiology/fullarticle/2844582)
- **Published At:** 2026-03-01T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
This randomized clinical trial examines data via prespecified analysis to evaluate the bleeding risk of the novel factor XI inhibitor abelacimab vs rivaroxaban in patients with atrial fibrillation (AF) according to their age (<75 vs ≥75 years).
## Clinical Analysis & Structured Key Points
JAMA Cardiology published a clinical update in Cardiology on 01 Mar 2026. The item focuses on Abelacimab vs Rivaroxaban in Older Individuals With AF. Review the original article for the full source wording and details.
## Related Clinical Research

- [New oral anticoagulants linked to slower cognitive decline in Alzheimer’s patients with AFib](https://medichelpline.com/clinical-feed/medical-news-today-0-new-oral-anticoagulants-may-help-slow-cognitive-decline-in-alzheimer-s-disease.md)
- [NOAC monotherapy vs NOAC+clopidogrel by age in AF patients with drug-eluting stents](https://medichelpline.com/clinical-feed/pubmed-42546025.md) (DOI: 10.1093/ageing/afag224)
- [Clinical Outcomes of Switching vs. Continuing Direct Oral Anticoagulants (DOACs) After Ischemic Stroke in Patients with Atrial Fibrillation in the US](https://medichelpline.com/clinical-feed/medrxiv-7-clinical-outcomes-of-switching-vs-continuing-direct-oral-anticoagulants-doacs.md)
- [Bleeding Risk in Atrial Fibrillation: Apixaban or Rivaroxaban With Diltiazem vs Metoprolol](https://medichelpline.com/clinical-feed/annals-of-internal-medicine-87-the-risk-for-bleeding-in-patients-with-atrial-fibrillation-from-concomitant-use-of-apixaban-or-rivaroxaban-with-diltiazem-compared-with-metoprolol.md)
- [Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.